List of Infugem drug patents

Infugem is owned by Sun Pharm.

Infugem contains Gemcitabine Hydrochloride.

Infugem has a total of 1 drug patent out of which 0 drug patents have expired.

Infugem was authorised for market use on 16 July, 2018.

Infugem is available in solution;intravenous dosage forms.

The generics of Infugem are possible to be released after 01 July, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9241948 SUN PHARM Ready to be infused gemcetabine solution
Jul, 2033

(10 years from now)

Drugs and Companies using GEMCITABINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 July, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in